11.62
-0.48 (-3.97%)
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Jade Biosciences, Inc. | Menaik | - |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.88 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.04% |
| % Dimiliki oleh Institusi | 33.40% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Great Point Partners I Lp | 30 Sep 2025 | 632,599 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 28.00 (BTIG, 140.96%) | Beli |
| Median | 25.00 (115.15%) | |
| Rendah | 17.00 (Guggenheim, 46.30%) | Beli |
| Purata | 23.33 (100.78%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 11.53 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Clear Street | 25 Nov 2025 | 25.00 (115.15%) | Beli | 12.54 |
| Guggenheim | 18 Nov 2025 | 17.00 (46.30%) | Beli | 12.65 |
| BTIG | 09 Oct 2025 | 28.00 (140.96%) | Beli | 9.40 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |